Exelixis, Inc.

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat.

After operating in the challenging biotech sector for nearly three decades, we’ve evolved into a multi-platform cancer company with a proven track record of resiliency in the face of adversity. The success of our flagship commercial product set us up on our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve.

Cancer is our cause. Make it yours, too.

Please see our Community Guidelines.

For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

1851 Harbor Bay Parkway
Alameda, California 94502 US
NEWS
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
This morning, the two companies announced the positive topline results from the pivotal Phase III CheckMate -9ER study in previously untreated patients with renal cell carcinoma.
It was a very busy week for clinical trial news. Here’s a look.
In 2014, Exelixis’ Cabometyx (cabozantinib) failed to show survival benefit as a monotherapy in prostate cancer.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
The Phase III trial paired Exelixis and Genentech’s Cotellic with a checkpoint inhibitor in advanced melanoma.
JOBS
IN THE PRESS